Evidence map›Paper›PMID 29245991›Full record

ArticleOncotarget2017

The impact of metformin use on survival in prostate cancer: a systematic review and meta-analysis.

Yao Xiao, Lei Zheng, Zubing Mei, Changbao Xu, Changwei Liu, Xiaohan Chu, Bin Hao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Melatonin May Increase Anticancer Potential of Pleiotropic Drugs.International journal of molecular sciences · 2018
    Review
  13. Pleiotropic Effects of Metformin on Cancer.International journal of molecular sciences · 2018
    Review
  14. Article
  15. Adjuvant effects of chemotherapeutics and Metformin on MFE-319 endometrial carcinoma cell line.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
  16. Role of Adiponectin in prostate cancer.International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yao XiaoDepartment of Urology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Lei ZhengDepartment of Endocrinology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
Zubing MeiDepartment of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Changbao XuDepartment of Urology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Changwei LiuDepartment of Urology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Xiaohan ChuDepartment of Urology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Bin HaoDepartment of Urology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Second Affiliated Hospital of Zhengzhou University · CNFirst Affiliated Hospital of Chinese PLA General Hospital · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetformin has been implicated to reduce the risk of prostate cancer (PCa) beyond its glucose-lowering effect. However, the influence of metformin on prognosis of PCa is often controversial.

resultsA total of 13 cohort studies encompassing 177,490 individuals were included in the meta-analysis. Data on overall survival (OS) and cancer-specific survival (CSS) was extracted from 8 and six studies, respectively. Comparing metformin users with non-metformin users, the pooled hazard ratios (HRs) for OS and CSS were 0.79 (95% confidence interval [CI] 0.63-0.98) and 0.76 (95% CI 0.57-1.02), respectively. Subgroup analyses stratified by baseline charcteristics indicated significant CSS benefits were noted in studies conducted in USA/Canada with prospective, large sample size, multiple-centered study design. Five studies reported the PCa prognosis for recurrence-free survival (RFS) and metformin use was significantly associated with patient RFS (HR 0.74, 95% CI, 0.58-0.95).

methodsRelevant studies were searched and identified using PubMed, Embase and Cochrane databases from inception through January 2017, which investigated associations between the use of metformin and PCa prognosis. Combined HRs with 95% CI were pooled using a random-effects model. The primary outcomes of interest were OS and CSS.

conclusionsOur findings provide indication that metformin therapy has a trend to improve survival for patients with PCa. Further prospective, multi-centered, large sample size cohort studies are warranted to determine the true relationship.

Indexed as

meta-analysismetforminprognosisprostate cancersurvival

Identifiers

PMID29245991
PMCPMC5725033
OpenAlexW2766655039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.